ArticleCurrent oncology (Toronto, Ont.)2021

Complete and Durable Response to Nivolumab in Recurrent Poorly Differentiated Pancreatic Neuroendocrine Carcinoma with High Tumor Mutational Burden.

Nai-Wen Kang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.